Indiana, US-based medical laboratory Genezen Laboratories has commenced construction of a new cGMP-compliant Lentiviral vector production facility.
The company has collaborated with DPS Group for the construction of more than 75,000ft2 advanced facility to produce lentivirus vectors.
Go deeper with GlobalData
The initial phase of the project will involve construction of a 25,000ft2 plant, which is planned to be completed this autumn.
This site will include a process development lab expansion, which will allow optimised closed and continuous processes to produce viral vectors.
The remaining phases of the production facility is scheduled to be completed in early 2022.
See Also:
The new vector production facility will feature many cGMP production suites that include capabilities for host cell banking viral vector production and host cell expansion, via transient transfection and producer cell lines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt will also include analytical testing services, which will include Recombinant Competent Lentivirus (RCL) testing, safety and sterility testing and vector stability testing.
Genezen stated that the vector product will be aseptically filled in the sterile bags.
Private equity firm Ampersand Capital Partners is providing majority funding for the new facility.
Genezen chairman and CEO Bill Vincent said: “The cell and gene therapy sector is evolving rapidly, and there’s growing demand for capacity and expertise.
“Building on recognized expertise in lentiviral and retroviral vector platforms, and leveraging the CDMO experience of our investor Ampersand, we are investing heavily to meet this need now, and in the future.
“Our new facility will support clients with the latest technologies as they develop and deliver life-changing therapeutics to patients.”
———————————————————————————————————————
Genezen begins construction of new Lentiviral vector production facility. Credit: Genezen Laboratories.
